PrEP for HIV Prevention: Effectiveness, Types & Key Considerations

Pre-exposure prophylaxis (PrEP) is a biomedical intervention where HIV-negative individuals take antiretroviral medication to prevent HIV acquisition. When taken consistently, PrEP reduces HIV risk by up to 99% for sexual transmission and ≥74% for injection drug use. It is a cornerstone of ending the HIV epidemic.

Types of PrEP

  • Oral Daily PrEP:
    • TDF/FTC (Truvada®, generics): Approved 2012. All genders, all exposure routes. Renal/bone monitoring needed.
    • TAF/FTC (Descovy®): Approved 2019. MSM and transgender women only (not studied in cisgender women for vaginal exposure). Less renal/bone toxicity.
  • On-Demand (2-1-1) PrEP: TDF/FTC only: 2 pills 2–24h before sex, 1 pill 24h later, 1 pill 24h after that. Only for MSM (studied in IPERGAY, ANRS IPERGAY). Not for women or people with HBV (flare risk).
  • Long-Acting Injectable PrEP:
    • Cabotegravir (Apretude®): 600 mg IM every 2 months (after 2 initiation doses 1 month apart). Approved 2021 for adults/adolescents ≥35 kg at risk sexually. HPTN 083 (MSM/TGW): 66% more effective than daily TDF/FTC. HPTN 084 (cisgender women): 89% more effective. No renal/bone concerns. Requires clinic visits.

Factors Influencing Effectiveness

  1. Adherence (the #1 factor): Daily PrEP requires ≥4 doses/week for women (cervicovaginal tissue), ≥2 doses/week for MSM (rectal tissue). Missed doses = lost protection. Injectable eliminates adherence gap.
  2. Partner's viral load: PrEP + partner's ART (U=U) = near-zero risk. Synergistic protection.
  3. Concurrent STIs: STIs (especially HSV-2, syphilis, gonorrhea, chlamydia) and bacterial vaginosis increase HIV susceptibility 2–5x. Regular STI screening/treatment enhances PrEP effectiveness.
  4. Drug interactions: Rare for TDF/FTC/TAF; monitor with CAB (rifampin, certain antiseizure meds reduce levels).
  5. Renal/hepatic function: TDF contraindicated if eGFR <60; TAF/CAB preferred. Monitor eGFR q6mo on TDF.
  6. Pregnancy/breastfeeding: TDF/FTC safe; TAF/CAB insufficient data.
  7. Substance use: Methamphetamine, alcohol associated with lower adherence. Integrate SUD care.

Monitoring on PrEP

  • HIV test (4th-gen Ag/Ab or NAT) every 3 months (oral), or at each injection visit (CAB).
  • Renal function (eGFR) at baseline, 3 mo, then q6mo (TDF); baseline only (TAF/CAB).
  • STI screening (3-site: pharyngeal, rectal, urethral/vaginal) q3–6mo.
  • Pregnancy test if applicable.
  • Hepatitis B status (TDF/FTC/TAF treat HBV; stopping can cause flare).

PrEP is safe, highly effective, and available in multiple formulations to fit diverse lives. It is a powerful tool for sexual health autonomy. Talk to a provider about which option is right for you.

HIV & AIDS - Related Articles

Health Sciences © https://www.222health.com